Cardio-Oncology and Multi-Imaging Modalities
Open Access
- 18 June 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4353
Abstract
Early detection and the rise of targeted cancer treatment have led to increased overall survival and decreased mortality among cancer patients. As the cancer survivor population ages, there is an increased risk for cardiovascular disease due to pre-existing comorbidities, deconditioning during therapy, or the natural progression of aging. Furthermore, with emerging oncologic therapies, there is an increased recognition of their potential cardiovascular toxicities. Indeed, heart disease is the leading cause of death in cancer survivors, which may reflect upon both the success of novel oncologic therapies and their potential cardiovascular toxicities. This recognition has driven the development of cardio-oncology, a multi-disciplinary field that involves collaboration between hematologists, oncologists, and cardiologists to screen, prevent, and manage cardiovascular disease in cancer patients and cancer survivors. The field focuses on early cardiovascular detection and prevention for these patients before, during, and after their oncologic treatment. As oncologic therapies evolve and our knowledge of short- and long-term adverse cardiovascular effects grows, it is critical for physicians to identify those at risk for increased morbidity and mortality, while also balancing the importance of their oncologic treatment plan. Multimodality cardiac imaging is the crux of the diagnosis and surveillance of these patients within cardio-oncology, and includes echocardiography, nuclear, computed tomography (CT), and cardiac magnetic resonance (CMR). Cardiac imaging is essential to establish the baseline function and assess various cardiotoxicities, including left ventricular dysfunction, heart failure, atherosclerosis, vascular injury, and arrhythmias. This review will discuss common oncologic therapies and their cardiotoxic profiles, the cardiac multimodality imaging modalities used in cardio-oncology, and the various approaches for the diagnosis and surveillance of this population.Keywords
This publication has 56 references indexed in Scilit:
- Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated CardiotoxicityCurrent Oncology Reports, 2024
- Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?Cardiovascular Drugs and Therapy, 2024
- Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapiesBreast Cancer Research and Treatment, 2021
- Cardiotoxicity of Radiation Therapy: Mechanisms, Management, and MitigationCurrent Treatment Options in Oncology, 2021
- The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated ReviewCardiovascular Drugs and Therapy, 2021
- 5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden DeathCurrent Cardiology Reports, 2021
- Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced CardiotoxicityJAMA Cardiology, 2019
- Cardiovascular Adverse Events Associated With BRAF and MEK InhibitorsJAMA Network Open, 2019
- Ischemic Heart Disease: Special Considerations in Cardio-OncologyCurrent Treatment Options in Cardiovascular Medicine, 2017
- Melphalan‐Induced Supraventricular Tachycardia: Incidence and Risk FactorsClinical Cardiology, 2011